Pioneering diagnostics
E.g., 26/04/2019
E.g., 26/04/2019
PreviousNext

2017 Financial Results

28 February, 2018

  • Excellent sales momentum in 2017 with a 10.2% increase in sales, at constant exchange rates and scope of consolidation:
    • €2,288 million in sales
    • Up 8.8% as reported
  • Strong 12.4% increase in contributive operating income before non-recurring items...

bioMérieux – Fourth-Quarter 2017 Business Review

23 January, 2018

  • Excellent sales momentum in 2017 with 10.2% growth in sales, at constant exchange rates and scope of consolidation:
    • €2,288 million in sales
    • Up 8.8% as reported...

CNES and bioMérieux extend their collaboration on Aquapad, a unique water quality testing tool

15 January, 2018

Monday 15 January in Marcy l’Étoile (near Lyon), Proxima mission astronaut Thomas Pesquet detailed, during a conference, lessons learned from the Aquapad experiment he performed on the International Space Station (ISS). Developed jointly by CNES and bioMérieux, a world leader in ...

CNES and bioMérieux extend their collaboration on Aquapad, a unique water quality testing tool

15 January, 2018

Monday 15 January in Marcy l’Étoile (near Lyon), Proxima mission astronaut Thomas Pesquet detailed, during a conference, lessons learned from the Aquapad experiment he performed on the International Space Station (ISS). Developed jointly by CNES and bioMérieux, a world leader in ...

Alexandre Mérieux appointed Chairman and CEO of bioMérieux

15 December, 2017

The Board of Directors of bioMérieux met today and approved the appointment of Alexandre Mérieux as Chairman and CEO of the Company, taking effect immediately.
After serving as Deputy CEO of bioMérieux for the last...

bioMérieux – Business review for the nine months ended September 30, 2017

18 October, 2017

  • Solid growth in sales, up 10.7% at constant exchange rates and scope of consolidation
    • €1,674 million in sales
    • Up 10.8% as reported
  • In microbiology, growth accelerated to nearly 8%
  • Contribution from all regions to the Group's strong...

bioMérieux – First-Half 2017 Results

30 August, 2017

bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

31 July, 2017

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® MS, its MALDI-TOF1 Mass...

Sysmex and bioMérieux Agreed to Dissolve the Joint Venture Sysmex bioMérieux Co., Ltd.

27 July, 2017

Sysmex Corporation (“Sysmex”) and bioMérieux S.A. (“bioMérieux”) (Paris:BIM) announce they have agreed to transfer all of Sysmex’ holdings in Sysmex bioMérieux Co., Ltd. (Tokyo, Japan) to bioMérieux thereby dissolving the joint venture created by and between the...

Second-Quarter 2017 Business Review

20 July, 2017

  • Good sales dynamic confirmed in second-quarter 2017, with sales up 11.3% over the first half at constant exchange rates and scope of consolidation:
    • €1,134 million in sales
    • Up 13.3% as reported
  • Noticeable...

PreviousNext